NCT01533506No Longer Available不适用
Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Mayo Clinic
- 试验地点
- 1
研究概览
简要总结
The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 11 Years 至 —（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic EncephalopathiesDravet SyndromeEpileptic Encephalopathies Associated With SCN1A MutationsNCT02239276Cook Children's Health Care System
No Longer Available
不适用
Compassionate Use of Stiripentol in Dravet SyndromeDravet SyndromeNCT01835314University of Colorado, Denver
招募中
不适用
Stiripentol (diacomit(R)) for refractory epilepsy patients with autoimmune encephalitisrefractory epilepsyJPRN-UMIN000023741agoya City University6
已完成
Unknown
se of the antiepileptic drug stiripentol for the treatment of severe myoclonic epilepsy in infancy (SMEI)Dravet syndrome (severe myoclonic epilepsy in infancy: SMEI)JPRN-jRCT1091220014Yushi InoueNational Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders10
Approved For Marketing
不适用
Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet SyndromeDravet SyndromeNCT01983722Children's Hospital Medical Center, Cincinnati